Literature DB >> 23692150

Histone deacetylase (HDAC) inhibitors as single agents induce multiple myeloma cell death principally through the inhibition of class I HDAC.

Sridurga Mithraprabhu, Tiffany Khong, Simon S Jones, Andrew Spencer.   

Abstract

Entities:  

Keywords:  Class I HDAC; HDAC6; histone deacetylase inhibitors; multiple myeloma

Mesh：

Substances：

Year:  2013        PMID： 23692150     DOI： 10.1111/bjh.12388

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  18 in total

1.  Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma.

Authors:  Dan T Vogl; Noopur Raje; Sundar Jagannath; Paul Richardson; Parameswaran Hari; Robert Orlowski; Jeffrey G Supko; David Tamang; Min Yang; Simon S Jones; Catherine Wheeler; Robert J Markelewicz; Sagar Lonial
Journal:  Clin Cancer Res       Date:  2017-01-04       Impact factor: 12.531

Review 2.  The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma.

Authors:  Claudia V Andreu-Vieyra; James R Berenson
Journal:  Ther Adv Hematol       Date:  2014-12

3.  Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma.

Authors:  Sridurga Mithraprabhu; Anna Kalff; Annie Chow; Tiffany Khong; Andrew Spencer
Journal:  Epigenetics       Date:  2014-11       Impact factor: 4.528

4.  NEDD9 regulates actin dynamics through cortactin deacetylation in an AURKA/HDAC6-dependent manner.

Authors:  Varvara K Kozyreva; Sarah L McLaughlin; Ryan H Livengood; Robin A Calkins; Laura C Kelley; Anuradha Rajulapati; Ryan J Ice; Matthew B Smolkin; Scott A Weed; Elena N Pugacheva
Journal:  Mol Cancer Res       Date:  2014-02-26       Impact factor: 5.852

5.  Analysis of the interplay between all-trans retinoic acid and histone deacetylase inhibitors in leukemic cells.

Authors:  Katrin Noack; Nisintha Mahendrarajah; Dorle Hennig; Luisa Schmidt; Florian Grebien; Dagmar Hildebrand; Markus Christmann; Bernd Kaina; Andreas Sellmer; Siavosh Mahboobi; Katharina Kubatzky; Thorsten Heinzel; Oliver H Krämer
Journal:  Arch Toxicol       Date:  2016-11-02       Impact factor: 5.153

6.  Molecular Mechanism of the Cell Death Induced by the Histone Deacetylase Pan Inhibitor LBH589 (Panobinostat) in Wilms Tumor Cells.

Authors:  Tao Yan-Fang; Li Zhi-Heng; Xu Li-Xiao; Fang Fang; Lu Jun; Li Gang; Cao Lan; Wang Na-Na; Du Xiao-Juan; Sun Li-Chao; Zhao Wen-Li; Xiao Pei-Fang; Zhao He; Su Guang-Hao; Li Yan-Hong; Li Yi-Ping; Xu Yun-Yun; Zhou Hui-Ting; Wu Yi; Jin Mei-Fang; Liu Lin; Ni Jian; Hu Shao-Yan; Zhu Xue-Ming; Feng Xing; Wang Jian; Pan Jian
Journal:  PLoS One       Date:  2015-07-15       Impact factor: 3.240

7.  Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome.

Authors:  P Tan; A Wei; S Mithraprabhu; N Cummings; H B Liu; M Perugini; K Reed; S Avery; S Patil; P Walker; P Mollee; A Grigg; R D'Andrea; A Dear; A Spencer
Journal:  Blood Cancer J       Date:  2014-01-10       Impact factor: 11.037

8.  Overcoming inherent resistance to histone deacetylase inhibitors in multiple myeloma cells by targeting pathways integral to the actin cytoskeleton.

Authors:  S Mithraprabhu; T Khong; A Spencer
Journal:  Cell Death Dis       Date:  2014-03-20       Impact factor: 8.469

Review 9.  Novel agents in the treatment of multiple myeloma: a review about the future.

Authors:  Leonard Naymagon; Maher Abdul-Hay
Journal:  J Hematol Oncol       Date:  2016-06-30       Impact factor: 17.388

Review 10.  The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective.

Authors:  Jesus F San-Miguel; Hermann Einsele; Philippe Moreau
Journal:  Adv Ther       Date:  2016-09-27       Impact factor: 3.845
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.